The Drug Regulatory Authority of Pakistan (DRAP) has been operating without a Chief Executive Officer (CEO) for over two weeks, leading to significant disruptions in the country’s pharmaceutical regulatory affairs. The absence of leadership has delayed approvals for life-saving medicines, Active Pharmaceutical Ingredients (APIs), and essential medical imports, putting Pakistan’s healthcare sector at risk.

Pharmaceutical companies and healthcare professionals have expressed concerns over prolonged regulatory delays, warning of potential shortages of critical drugs and medical devices. Customs authorities have also begun holding back pharmaceutical shipments due to pending regulatory approvals, further aggravating the crisis.

Industry experts urge the government to appoint a qualified CEO immediately to restore regulatory efficiency, ensure uninterrupted medical supplies, and prevent a worsening healthcare crisis. Swift action is needed to stabilize DRAP’s operations and safeguard public health.